Effects of antipsoriatic therapies on aberrant IL-6/STAT3 signaling in psoriasis (B07)

• Subject Area: Dermatology
• Term: from 2015 to 2019
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 246807620

Psoriasis is a Th17-mediated skin inflammation with aberrant keratinocyte cell signaling, genetic and epigenetic alterations. Interestingly, psoriasis responds to very distinct treatments like anthralin, PUVA phototherapy, anti-TNF or anti-p40. In contrast to therapies neutralizing cytokines, anthralin and PUVA both even induce inflammatory mediators like IL-6 and ROS. By studying human and murine keratinocytes and immune cells in Th17-skin inflammation we want to identify the therapy-induced IL-6/STAT3- and ROS-dependent molecular events on these cell types and the resulting IL-23/Th17 response. The CRC allows us an improved understanding of the crosstalk between these cell types.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 156: The skin as sensor and effector orchestrating local and systemic immunity
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Co-Applicant Institution: Eberhard Karls Universität Tübingen
• Project Heads: Dr. Franziska Eberle; Professor Dr. Kamran Ghoreschi